Recordati rises on publication of confident three-year plan

9 February 2017

Italian drugmaker Recordati (RECI: MI) has not only announced an increase in revenue for 2016 of more than 10%, but has also predicted that it will rise by a further 26% by 2019.

The Recordati family owns a 51% stake in the company but has a presence on the Italian stock exchange, and investors seemed to like what they saw of the preliminary annual results as its share price rose by 3.5% to 27.95 euros on Thursday after the annual results and a three-year business plan were published.

"My priority will be to proceed along the lines of the development strategy outlined by Giovanni Recordati with the objective of continuing the internationalization and growth of the group"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK